Adalta Ltd has released a press release.
Non-renounceable Rights Issue Offer
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from AdAlta
- Placement and Rights Offer
- Investor presentation including future milestones
- First participants treated in AD-214 Phase I trial
- Supportive US FDA pre-IND meeting results for AD-214
- AdAlta receives approval to commence AD-214 Phase I trial
Later from AdAlta
- GE Healthcare collaboration progresses
- Investor Presentation - BIO investor forum
- AusBiotech presentation including Phase I status update
- AGM Presentation
- Phase I HV extension to explore encouraging results
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta